Premium
Safety concern clouds outcome of baclofen study for alcohol dependence
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30353
Subject(s) - baclofen , agonist , medicine , adverse effect , alcohol , alcohol dependence , pharmacology , anesthesia , receptor , chemistry , biochemistry
A 12‐week study has found that the selective gamma‐aminobutyric acid (GABA) receptor agonist baclofen improved drinking outcomes in patients with alcoholic liver disease. However, a high prevalence of serious adverse events among patients taking a higher dose of the study medication raises concerns about how widely used this treatment option should become.